Developing new drugs to treat dormant malaria parasites
Lead optimization and target identification of drugs targeting hypnozoites
This study is working on new medications to help people with malaria caused by the Plasmodium vivax parasite, especially those who have a specific genetic condition, by targeting the dormant forms of the parasite that can cause relapses.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Georgia NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project ID | NIH-10903784 on NIH RePORTER |
What this research studies
This research focuses on creating and optimizing new medications specifically designed to target hypnozoites, the dormant forms of the malaria parasite Plasmodium vivax. These hypnozoites can remain inactive in the liver for extended periods and later reactivate, causing relapsing malaria. The project employs innovative liver culture systems to enhance drug development and aims to identify specific biological targets for these drugs. By utilizing advanced techniques in medicinal chemistry and chemical biology, the research seeks to provide safer and more effective treatments for patients, particularly those with glucose-6-phosphate dehydrogenase deficiency.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with relapsing malaria caused by Plasmodium vivax, especially those who may have glucose-6-phosphate dehydrogenase deficiency.
Not a fit: Patients with other forms of malaria or those who do not have relapsing malaria may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective treatments for relapsing malaria, significantly improving patient outcomes.
How similar studies have performed: While there has been limited success in targeting dormant malaria forms, this approach is considered novel and aims to fill a significant gap in current malaria treatment options.
Where this research is happening
Athens, United States
- University of Georgia — Athens, United States (Active)
Researchers
- Principal investigator: Kyle, Dennis E — University of Georgia
- Study coordinator: Kyle, Dennis E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.